Ursodeoxycholic acid capsule product introduction Common name: Ursodeoxycholic acid capsule
Manufacturer: Sichuan Keruide Pharmaceutical Co., Ltd.
Approval number: National Medicine Zhunzi H20 123205
Drug specification: 0.25g*30 capsules.
Drug price: ￥285.
Product introduction of ursodeoxycholic acid capsules The famous Disheng ursodeoxycholic acid capsules
Commonly known as ursodeoxycholic acid capsules
English name ursodeoxycholic acid capsule
Chinese pinyin ursodeoxycholic acid capsules
The main ingredient is potatoes. Chemical name: 3? ,7? -Dihydroxy -5? -Cholestane -24- acid; Molecular formula: c24h40o4; Molecular weight: 392.58
Properties white opaque hard capsules, the contents are white powder or granules.
indicate
1. Sterol gallstones? It must be a stone that can be penetrated by X-rays, and the gallbladder contraction function must be normal;
2. Cholestasis liver disease (such as primary biliary cirrhosis);
3. Bile reflux gastritis.
dosage
1. Cholesterol gallstones and cholestatic liver disease should be taken with a small amount of water on time. The daily dose according to body weight is 10mg/kg, that is, litholysis treatment: it usually takes 6 ~ 24 months. If the calculus does not get smaller after taking 12 months, stop taking it, and the treatment result will be judged according to ultrasonic or X-ray examination every 6 months.
2. Bile reflux gastritis is swallowed with water before going to bed at night, and must be taken regularly, one capsule (250mg) at a time, once a day. Generally take 10 ~ 14 days, and decide whether to continue taking the medicine according to the doctor's advice.
pharmacokinetics
1. absorption: after oral administration, Yusuf is mainly absorbed in the upper jejunum by non-ionic passive diffusion and in the ileum by active transport. The absorption of UDCA is negatively correlated with the severity of cholestasis (based on serum bilirubin level). The first-pass effect is large, and 50-75% of the oral dose is absorbed by the liver.
2. Distribution: After absorption, it is mainly distributed in liver and intestine tissues and plasma, and the protein binding rate of plasma is 96-99%. The curative effect of youshufu mainly depends on the concentration of UDCA in bile. After taking UDCA at the dose of 10- 15mg/kg/d, the concentration of UDCA in bile increased in a dose-dependent manner until it reached a plateau. UDCA accounts for 40-60% of bile acids in patients with gallstones. The absorption of bile acid colloidal particles in duodenal bile of patients with liver disease decreased, while the proportion of UCDA in bile was slightly lower. It can penetrate the blood-brain barrier. In vitro experiments have proved that UDCA may have protective effect on brain cells of patients with liver disease, because it can inhibit the apoptosis of astrocytes.
3. Metabolism and excretion: In the liver, UDCA combines with glycine, taurine, N- acetylglucosamine, glucuronic acid and sulfate, and in the colon, UDCA can also be metabolized by intestinal bacteria. A small part of metabolites are excreted through urethra, and most of them are excreted through feces. The biological half-life of oral UDCA is 3.5-5.8 days.
counteraction
1. Calcification of gallstones may occur during the treatment of gallstones. A few cases are rubella and loose stool.
2. In the treatment of advanced primary biliary cirrhosis, decompensation of cirrhosis can be seen occasionally, and it will be recovered after stopping the drug.
3. In the treatment of primary biliary cirrhosis, very few cases will have severe right upper abdominal pain.
Matters needing attention
1. ursodeoxycholic acid capsules must be used under the supervision of a doctor.
2. The attending physician must check some liver function indexes such as AST(SGOT), ALT(SGPT) and? G T and so on. , and then check the liver function index every 3 months.
3. In order to evaluate the therapeutic effect and find the calcification of gallstones early, X-ray examination of gallbladder (oral cholecystography) should be performed 6 ~ 1 month after the start of treatment according to the size of gallstones. X-ray photos were taken in standing position and lying position (ultrasonic monitoring).
taboo
1. Onset of acute cholecystitis and cholangitis.
2. Patients with complete biliary obstruction and calcification of gallstones.
3. Pregnant and lactating women.
Pregnant women and pregnancy drugs through animal studies, it is found that the use of ursodeoxycholic acid in early pregnancy will have embryonic toxicity. There is still a lack of experimental data in the first three months of pregnancy. Women of childbearing age can only use ursodeoxycholic acid capsules after taking safe contraceptive measures. Before starting treatment, the patient must rule out pregnancy. For safety reasons, ursodeoxycholic acid capsules should not be taken in the first three months of pregnancy.
Elderly patients should use drugs with caution.
Excessive medication can lead to diarrhea. Generally speaking, due to the malabsorption of ursodeoxycholic acid with higher dose, it is excreted too much with feces, and there is little excess. If diarrhea occurs, the reducing agent is the most; If diarrhea persists, stop treatment. Diarrhea can be treated symptomatically, such as supplementing fluids and electrolytes, and no other special treatment is needed.
Drug Interaction Ursodeoxycholic Acid Capsules should not be the same as those of Coleenamine, cholantin, Aluminum Hydroxide and/or Aluminum Hydroxide-magnesium trisilicate Capsules, because these drugs can combine with Ursodeoxycholic Acid in the intestine, thus hindering absorption and affecting curative effect. If you must take the above drugs, you should take ursodeoxycholic acid capsules two hours before or two hours after taking them.
Storage seal.
Packaging 12 capsules/box.
Valid for 24 months.
Manufacturer Sichuan Keruide Pharmaceutical Co., Ltd.
Efficacy and function of ursodeoxycholic acid capsule (core) Is the indication of ursodeoxycholic acid capsule (core) cholesterol gallstone? It must be a stone that can be penetrated by X-rays, and the gallbladder contraction function must be normal; Cholestasis liver disease (such as primary biliary cirrhosis); Bile reflux gastritis
Frequently asked questions about the use of ursodeoxycholic acid capsules Q: What are the indications of ursodeoxycholic acid capsules (with cores)?